Our findings underscored the TRIM16/NFKBIZ/p65 axis played a pivotal role in regulating HCC progression and NFKBIZ as a promising therapeutic and prognostic target for HCC, as well as a potential target to enhance sorafenib sensitivity for HCC treatment. This evidence concerns the gene TRIM16 and hepatocellular carcinoma.